Pharmaceutical companies often argue that the list price for their products doesn’t really matter because that’s not the real price that anybody pays, however, the truth is, it does matter. High list prices drive patients into and out of the dreaded “doughnut hole” faster, raising both their out-of-pocket costs and Medicare expenditures. Read more here. (Source: Managed Care, 5/30/17)
Connected. Community.
